Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
During persistent viral infections, chronic immune activation, negative immune regulator expression, an elevated interferon signature, and lymphoid tissue destruction correlate with disease progression. We demonstrated that blockade of type I interferon (IFN-I) signaling using an IFN-I receptor neutralizing antibody reduced immune system activation, decreased expression of negative immune regulatory molecules, and restored lymphoid architecture in mice persistently infected with lymphocytic choriomeningitis virus. IFN-I blockade before and after establishment of persistent virus infection resulted in enhanced virus clearance and was CD4 T cell-dependent. Hence, we demonstrate a direct causal link between IFN-I signaling, immune activation, negative immune regulator expression, lymphoid tissue disorganization, and virus persistence. Our results suggest that therapies targeting IFN-I may help control persistent virus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationIMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
Guidotti, L. G., & Chisari, F. V. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100230 · Cited by 811
Cited by
Items 201–300 of 759
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
Zeng, H., Li, L., Hou, Z., Zhang, Y., Tang, Z., & Liu, S. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.43079 · Cited by 75
Jin, J., Mu, Y., Zhang, H., Sturmlechner, I., Wang, C., Jadhav, R. R., Xia, Q., Weyand, C. M., & Goronzy, J. J. (2023) · Nature Aging · doi:10.1038/s43587-023-00399-w · Cited by 77
Manipulating IL-10 signalling blockade for better immunotherapy
Ni, G., Wang, T., Walton, S. F., Zhu, B., Chen, S., Wu, X., Wang, Y., Wei, M. Q., & Liu, X. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.012 · Cited by 71
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 70
Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
Antonelli, G., Scagnolari, C., Moschella, F., & Proietti, E. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.12.006 · Cited by 73
“For instance the detrimental effects of type I IFN action are clearly demonstrable during lymphocytic choriomeningitis virus (LCMV), pathogenic simian immunodeficiency virus (SIV) and HIV infections where a direct causal link between type I IFN/ISGs expression and chronic immune activation and dysfunction has been rep…”
Odorizzi, P. M., & Wherry, E. J. (2013) · Science · doi:10.1126/science.1237568 · Cited by 68
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
Sex differences in HIV-1-mediated immunopathology
Ziegler, S. M., & Altfeld, M. A. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000237 · Cited by 71
“Although blocking of IFNa during acute infection had detrimental consequences on the outcome of the LCMV infection, blocking of IFNa during chronic LCMV infection allowed for enhanced immune control [68,69].”
BackgroundCircadian control of interferon-sensitive gene expression in murine skin
Greenberg, E. N., Marshall, M. E., Jin, S., Venkatesh, S., Dragan, M., Tsoi, L. C., Gudjonsson, J. E., Nie, Q. H., Takahashi, J. S., & D, B. A. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915773117 · Cited by 66
“First, excessive IFN responses worsens pathologies by reducing the effectiveness of the adaptive immune system, such as in chronic IFN signaling due to a lymphocytic choriomeningitis virus infection (40), indicating that the antiviral power of the IFN-activated pathways requires a balance between activating signals an…”
Shaabani, N., Duhan, V., Khairnar, V., Gassa, A., Ferrer-Tur, R., Häussinger, D., Recher, M., Zelinskyy, G., Liu, J., Dittmer, U., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.350 · Cited by 67
“Second, IFN-I upregulates IL-10 and PD-L1, and this upregulation contributes to the exhaustion of CD8 T cells.(8,9) Genetic deletion of IL-10 or partial blockade of PD-1 enhances the control of virus during chronic infection.”
Zhang, Y., Yeganeh, P. N., Zhang, H., Wang, S. Y., Li, Z., Gu, B., Lee, D.-J., Zhang, Z., Ploumakis, A., Shi, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01932-8 · Cited by 67
“So far, clinical attempts to activate IFNI using STING agonists have been disappointing, perhaps partly because chronic IFNI signaling promotes PD-L1 expression and reduces antigen-specific T cell trafficking, expansion, metabolic reprogramming and function 40,41 .”
Macrophage and T Cell Produced IL-10 Promotes Viral Chronicity
Richter, K., Perriard, G., Behrendt, R., Schwendener, R. A., Sexl, V., Dunn, R., Kamanaka, M., Flavell, R. A., Roers, A., & Oxenius, A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003735 · Cited by 63
Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection
Yamada, D. H., Elsaesser, H. J., Lux, A., Timmerman, J. M., Morrison, S. L., de la Torre, J. C., Nimmerjahn, F., & Brooks, D. G. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.005 · Cited by 65
“…observe a notable suppression of other Ab functions such as effective target binding, receptor blockade (Barber et al., 2006; Brooks et al., 2006; Teijaro et al., 2013; Wilson et al., 2013), or neutralization of infectious virus, suggesting that the non-Fc g R-medi-ated functions of Abs might…”
Callendret, B., Eccleston, H. B., Hall, S., Satterfield, W. C., Capone, S., Folgori, A., Cortese, R., Nicosia, A., & Walker, C. M. (2014) · Hepatology · doi:10.1002/hep.27278 · Cited by 63
“This cytokine that is sometimes necessary for CD8(1) T-cell differentiation,(21-23) but under some circumstances also limits effector function or survival(24-29) and contributes to virus persistence in murine models.(30,31) With oral dosing, a shorter duration of therapy, and reduced toxicity of direct-acting antivira…”
BackgroundDHX15 is required to control RNA virus-induced intestinal inflammation
Xing, J., Zhou, X., Fang, M., Zhang, E., Minze, L. J., & Zhang, Z. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109205 · Cited by 64
Lanna, A., Coutavas, E., Levati, L., Seidel, J., Rustin, M. H. A., Henson, S. M., Akbar, A. N., & Franzese, O. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301409 · Cited by 62
“It has been suggested that this may be a control mechanism that limits immunopathology that may arise from chronic stimulation in tissues (6, 60, 61).”
A Dual Role of Type I Interferons in Antitumor Immunity
Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 64
Pharmacological Inhibition of Type I Interferon Signaling Protects Mice Against Lethal Sepsis
Dejager, L., Vandevyver, S., Ballegeer, M., Wonterghem, E. V., An, L.-L., Riggs, J. M., Kolbeck, R., & Libert, C. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit600 · Cited by 62
“Accordingly, blocking type I IFN signaling also clears persistent viral infections [31, 32].”
BackgroundSuperoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage
Bhattacharya, A., Hegazy, A. N., Deigendesch, N., Kosack, L., Cupovic, J., Kandasamy, R. K., Hildebrandt, A., Merkler, D., Kühl, A. A., Vilagos, B., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.013 · Cited by 60
“As shown previously in Figure 7, the blockade of IFNAR1 resulted in protection from early hepatitis, yet it subsequently led to exacerbated concentrations of ALT 12 days after infection, coinciding with improved virus control that was likely driven by T cells (Figure S5C) (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundInfluentialInhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses
Meyer, B., & Ly, H. (2016) · Journal of Virology · doi:10.1128/jvi.03049-15 · Cited by 65
Nice, T. J., Osborne, L. C., Tomov, V. T., Artis, D., Wherry, E. J., & Virgin, H. W. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005684 · Cited by 61
Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells
Webster, B., Assil, S., & Dreux, M. (2016) · Journal of Virology · doi:10.1128/jvi.01692-16 · Cited by 57
“For instance, in a mouse model of chronic LCMV infection, long-term type I IFN-mediated immunosuppression was found to be associated with the induction of inhibitory signals that switch the antiviral regulation by type I IFNs during the acute phase of infection to a proviral function at the chronic stage (19, 20).”
BackgroundConfounding roles for type I interferons during bacterial and viral pathogenesis
Carrero, J. A. (2013) · International Immunology · doi:10.1093/intimm/dxt050 · Cited by 68
“Therefore, IFNAR plays a major role in the establishment of chronic infection with LCMV and neutralization of IFNAR has therapeutic potential for patients harboring chronic viral infections.”
BackgroundInfluentialTeijaro, J. R., Studer, S., Leaf, N., Kiosses, W. B., Nguyen, N., Matsuki, K., Negishi, H., Taniguchi, T., Oldstone, M. B. A., & Rosen, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525356113 · Cited by 59
Self-citationShepardson, K. M., Larson, K., Morton, R. V., Prigge, J. R., Schmidt, E. E., Huber, V. C., & Rynda‐Apple, A. (2016) · mBio · doi:10.1128/mbio.00506-16 · Cited by 61
Taylor, J. P., Cash, M. N., Santostefano, K. E., Nakanishi, M., Terada, N., & Wallet, M. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mia0917-352r · Cited by 60
Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice
Ayala, A. V., Hsu, C.-Y., Oles, R. E., Matsuo, K., Loomis, L. R., Buzun, E., Terrazas, M. C., Gerner, R. R., Lu, H.-H., Kim, S., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230063 · Cited by 66
Protozoan Parasites and Type I IFNs
Silva‐Barrios, S., & Stäger, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00014 · Cited by 68
Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL
Kannagi, M., Hasegawa, A., Nagano, Y., Kimpara, S., & Suehiro, Y. (2019) · Retrovirology · doi:10.1186/s12977-019-0484-z · Cited by 64
The role of viral persistence in flavivirus biology
Mlera, L., Melik, W., & Bloom, M. E. (2014) · Pathogens and Disease · doi:10.1111/2049-632x.12178 · Cited by 70
“A recent report showed that IFN blockade of type I IFN signaling results in a CD4 T cell-dependent clearance of LCMV Cl13 (Teijaro et al., 2013) .”
BackgroundXu, X., Qiu, C., Zhu, L., Huang, J., Li, L., Fu, W., Zhang, L., Wei, J., Wang, Y., Geng, Y., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401249 · Cited by 55
Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement
Smith, N., Pietrancosta, N., Davidson, S., Dutrieux, J., Chauveau, L., Cutolo, P., Dy, M., Scott‐Algara, D., Manoury, B., Zirafi, O., et al. (2017) · Nature Communications · doi:10.1038/ncomms14253 · Cited by 58
“Two recent studies have illustrated this deleterious effect, demonstrating that type I interferon facilitate persistent infection and disease progression in mice infected with lymphocytic choriomeningitis virus (LCMV) 50,51 .”
STING Agonists/Antagonists: Their Potential as Therapeutics and Future Developments
Guerini, D. (2022) · Cells · doi:10.3390/cells11071159 · Cited by 58
“Although the cGAS/STING pathway activation is considered one of the first defenses that the immune system deploys to fight against viral infection, once the acute phase is terminated, elevated type I interferon has been shown to propagate chronic inflammation that damages tissue and prevents tissue recovery [45,46].”
BackgroundMarx, A., Kallert, S. M., Brunner, T. M., Villegas, J. A., Geier, F., Fixemer, J., Abreu-Mota, T., Reuther, P., Bonilla, W. V., Fadejeva, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.029 · Cited by 64
Welten, S. P. M., Redeker, A., Franken, K. L. M. C., Oduro, J. D., OSSENDORP, F. A., Čičin‐Šain, L., Melief, C. J. M., Aichele, P., & Arens, R. (2015) · eLife · doi:10.7554/elife.07486 · Cited by 57
“Consistent with this, at 24 hr LCMV also induced higher expression of pro-inflammatory cytokines, which have been described to be downstream of type I IFN signaling (i.e., Rantes, IL-6, KC, Mip-1β and MCP-1) (Teijaro et al., 2013).”
BackgroundClement, M., Marsden, M., Stacey, M. A., Abdul-Karim, J., Brias, S. G., Bento, D. F. C., Scurr, M. J., Ghazal, P., Weaver, C. T., Carlesso, G., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006050 · Cited by 57
“Further, in the LCMV model of infection, blockade of type-I IFN receptor signaling in certain situations may enhance CD4 T cell immunity and control of virus chronicity, an outcome associated with reduced development of immune-suppressive DCs [35,36].”
BackgroundInfluentialWillemsen, J., Wicht, O., Wolanski, J., Baur, N., Bastian, S., Haas, D. A., Matula, P., Knapp, B. L., Meyniel‐Schicklin, L., Wang, C., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.021 · Cited by 63
Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon
Akiyama, H., Ramirez, N.-G. P., Gibson, G. A., Kline, C. E., Watkins, S. C., Ambrose, Z., & Gummuluru, S. (2017) · Journal of Virology · doi:10.1128/jvi.00972-17 · Cited by 57
Regulators of T‐cell fate: Integration of cell migration, differentiation and function
Groom, J. R. (2019) · Immunological Reviews · doi:10.1111/imr.12742 · Cited by 61
Mariotte, A., de Cauwer, A., Po, C., Fayçal, C. A., Pichot, A., Paul, N., Aouadi, I., Carapito, R., Frisch, B., Macquin, C., et al. (2020) · Theranostics · doi:10.7150/thno.40650 · Cited by 59
“immunosuppression [41], as demonstrated in the LCMV model [42, 43].”
BackgroundChen, Q., Li, Y., Wang, X., Zhang, X., Hu, Y., Li, L., Suo, D., Ni, K., Li, Z., Zhan, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1542 · Cited by 57
“One of them was CD8_C14-IFIT1, which uniquely expressed IFN-inducible genes, including IFIT1, IFIT3, IFI44L, IFI6, and ISG15 (Fig.”
BackgroundInfluentialMatthys, V. S., Cimica, V., Dalrymple, N. A., Glennon, N. B., Bianco, C., & Mackow, E. R. (2014) · Journal of Virology · doi:10.1128/jvi.02647-13 · Cited by 55
“Studies showed that hantavirus-infected endothelial cells elicit highlevel IFN-directed ISG responses at late times postinfection (21), which may actually be an inherent plan for hantaviruses to establish persistence within host endothelial cells (70, 71).”
BackgroundTET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Xue, S., Liu, C., Sun, X., Li, W., Zhang, C., Zhou, X., Lu, Y., Xiao, J., Li, C., Xu, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.068 · Cited by 59
Cai, B., Wu, J., Yu, X. H., Su, X., & Wang, R.-F. (2017) · mBio · doi:10.1128/mbio.02161-16 · Cited by 57
Racicot, K. E., Aldo, P. B., El-Guindy, A. S., Kwon, J., Romero, R. J., & Mor, G. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601824 · Cited by 57
Interferon regulatory factor 3 in adaptive immune responses
de Lendonck, L. Y., Martinet, V., & Goriely, S. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1653-9 · Cited by 61
“In the context of chronic LCMV infection, these effects are detrimental to the host and participate in virus persistence by generating “hyper-immune” activation [85, 86].”
Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection
Cooper, L., Xu, H. M., Polmear, J., Kealy, L. C., Szeto, C. W., Pang, E. S., Gupta, M., Kirn, A., Taylor, J. J., Jackson, K., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.016 · Cited by 57
“Although previous studies have compared IFN induction in LCMV-Armstrong versus LCMV-Clone13 in fine detail, 57,60,61 direct comparison of WE and Docile beyond the first 2 days post-infection 72 was lacking.”
Crosby, E. J., Clark, M. L., Novais, F. O., Wherry, E. J., & Scott, P. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500855 · Cited by 54
The viral innate immune antagonism and an alternative vaccine design for PRRS virus
Ke, H., & Yoo, D. (2017) · Veterinary Microbiology · doi:10.1016/j.vetmic.2017.03.014 · Cited by 59
“In contrast, recent studies show that the LCMV persistence in mice is controlled or lost when type I IFN signaling is blocked, demonstrating the paradoxical role of type I IFNs in viral persistence (Teijaro et al., 2013; Wilson et al., 2013).”
Type I Interferons and Malaria: A Double-Edge Sword Against a Complex Parasitic Disease
He, X., Xia, L., Tumas, K. C., Wu, J., & Su, X. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.594621 · Cited by 57
“, 2014) andmediate immunosuppression during chronic viral infections (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundTaleb, K., Auffray, C., Villefroy, P., Pereira, A. L., Hosmalin, A., Gaudry, M., & Bon, A. L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502638 · Cited by 53
Oldstone, M. B. A., Ware, B. C., Horton, L. E., Welch, M. J., Aiolfi, R., Zarpellon, A., Ruggeri, Z. M., & Sullivan, B. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804674115 · Cited by 55
“The (51)chromium assay has been reported in our publications (26, 53).”
BackgroundMethodInfluentialSelf-citationTLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women
Azar, P., Mejía, J. E., Cénac, C., Shaiykova, A., Youness, A., Laffont, S., Essat, A., Izopet, J., Passaes, C., Müller-Trutwin, M. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136047 · Cited by 57
“Here, blockade of IFN-I signaling, induced even before infection, promoted viral clearance (17, 18).”
BackgroundInfluentialZemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 55
Puttur, F. K., Arnold‐Schrauf, C., Lahl, K., Solmaz, G., Lindenberg, M., Mayer, C. T., Gohmert, M., Swallow, M., van Helt, C., Schmitt, H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003648 · Cited by 54
Interferon–microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis
Yang, Y., Lin, X., Lu, X., Luo, G., Zeng, T., Tang, J. P., Jiang, F., Li, L., Cui, X., Huang, W., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310318 · Cited by 56
Regulation of autoimmune and anti‐tumour T‐cell responses by PTPN 22
Brownlie, R. J., Zamoyska, R., & Salmond, R. J. (2018) · Immunology · doi:10.1111/imm.12919 · Cited by 63
“Excessive production of type 1 IFN following infection can result in T cell exhaustion (54, 55).”
BackgroundCytokines and persistent viral infections
Beltra, J., & Decaluwe, H. (2016) · Cytokine · doi:10.1016/j.cyto.2016.02.006 · Cited by 55
Jiang, L., Yao, S., Huang, S., Wright, J., Braciale, T. J., & Sun, J. (2016) · European Journal of Immunology · doi:10.1002/eji.201646548 · Cited by 51
“Thus, type I IFNs could display differing roles in regulating the development of inflammatory responses and immunity following viral infections, and their exact function in regulating inflammation and immunity would be dependent on the infectious organism as well as the timing and levels of the production of these plu…”
BackgroundDDX3 suppresses type I interferons and favors viral replication during Arenavirus infection
Loureiro, M. E., Zorzetto-Fernandes, A. L., Radoshitzky, S. R., Chī, X., Dallari, S., Marooki, N., Léger, P., Foscaldi, S., Harjono, V., Sharma, S., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007125 · Cited by 55
The integrated stress response mediates necrosis in murine Mycobacterium tuberculosis granulomas
Bhattacharya, B., Xiao, S., Chatterjee, S., Urbanowski, M. E., Ordoñez, A. A., Ihms, E. A., Agrahari, G., Lun, S., Berland, R., Pichugin, A. V., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci130319 · Cited by 53
Transcriptional and epigenetic regulation of T cell hyporesponsiveness
Pereira, R. M., Hogan, P. G., Rao, A., & Martinez, G. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ri0317-097r · Cited by 46
“Indeed, it has been previously suggested that type I IFNs induce exhaustion and viral persistence [80, 81].”
BackgroundScagnolari, C., & Antonelli, G. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.03.003 · Cited by 50
“Indeed, a direct causal link between type I IFN signaling, immune activation, negative immune regulator expression (e.g. IL-10 and PD-L1), lymphoid tissue disorganization, impaired humoral responses to secondary viral infection, and persistent LCMV has been reported [6] [7] [8] [9] .”
The uric acid crystal receptor Clec12A potentiates type I interferon responses
Li, K., Neumann, K., Duhan, V., Namineni, S., Hansen, A. L., Wartewig, T., Kurgyis, Z., Holm, C. K., Heikenwälder, M. F., Lang, K. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821351116 · Cited by 52
“However, during chronic LCMV infection, prolonged IFN-I signaling can facilitate virus persistence by inducing the expression of negative immune regulators, such as programmed death-ligand 1 and IL-10 (15, 16).”
BackgroundInfluentialIL-10: Achieving Balance During Persistent Viral Infection
Ng, C. T., & Oldstone, M. B. A. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-43492-5_6 · Cited by 52
“Infection with both ARM and CL-13 initiates the production of IFNα in the first 24 h (Teijaro et al. 2013; Wilson et al. 2013).”
BackgroundSelf-citationPérez-Girón, J. V., Belicha‐Villanueva, A., Hassan, E., Gómez‐Medina, S., Cruz, J. L. G., Lüdtke, A., Ruibal, P., Albrecht, R. A., García‐Sastre, A., & Muñoz‐Fontela, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400222 · Cited by 49
Planès, R., Haij, N. B., Leghmari, K., Serrero, M. C., BenMohamed, L., & Bahraoui, E. (2016) · Journal of Virology · doi:10.1128/jvi.00262-16 · Cited by 50
The Role of IFN-β during the Course of Sepsis Progression and Its Therapeutic Potential
Rackov, G., Shokri, R., Álvarez‐Mon, M., Martínez‐A, C., & Balomenos, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00493 · Cited by 54
“IFNα/β can nonetheless have detrimental immunosuppressive effects during chronic infection with certain viruses (56, 57).”
BackgroundDagenais-Lussier, X., Loucif, H., Murira, A., Laulhé, X., Stäger, S., Lamarre, A., & van Grevenynghe, J. (2017) · Viruses · doi:10.3390/v10010012 · Cited by 49
“Proper splenic architecture organization LCMV [23,26] Decreased CXCR4 expression on GC B Increased levels of specific Ab production and specific ASCs LCMV [52]”
BackgroundInfluentialAli, A., Canaday, L. M., Feldman, H. A., Cevik, H., Moran, M. T., Rajaram, S., Lakes, N., Tuazon, J. A., Seelamneni, H., Krishnamurthy, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146686 · Cited by 50
Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness
Isringhausen, S., Mun, Y., Kovtonyuk, L. V., Kräutler, N. J., Suessbier, U., Gomariz, Á., Spaltro, G., Helbling, P. M., Wong, H. C., Nagasawa, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20192070 · Cited by 51
“We hypothesized that remaining loss of CARc could be mediated by local IFNγ production, which can be further exacerbated in the context of type I IFN blockade (Teijaro et al., 2013).”
BackgroundMethodFueyo‐González, F., McGinty, M. T., Ningoo, M., Anderson, L., Cantarelli, C., Angeletti, A., Demir, M., Llaudó, I., Purroy, C., Marjanović, N., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.011 · Cited by 50
In Vitro and In Vivo Characterizations of Pichinde Viral Nucleoprotein Exoribonuclease Functions
Huang, Q., Shao, J., Lan, S., Zhou, Y., Xing, J., Dong, C., Liang, Y., & Ly, H. (2015) · Journal of Virology · doi:10.1128/jvi.00009-15 · Cited by 49
Dahlgren, M. W., Plumb, A. W., Niss, K., Lahl, K., Brunak, S., & Johansson‐Lindbom, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932388 · Cited by 52
“The LCMV clone 13 strain establishes a persistent infection where long-lasting expression of IFN-b and IFN-a in cDCs leads to exhaustion of the protective Th1 cell response by a mechanism involving up-regulation of PD-L1 and IL-10 expression by the cDCs (57, 58).”
BackgroundDervovic, D., Malik, A., Chen, E. L. Y., Narimatsu, M., Adler, N., Afiuni‐Zadeh, S., Krenbek, D., Martinez, S., Tsai, R., Boucher, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38841-7 · Cited by 56
“While the immune stimulatory roles of IFNs are better known, the immune-suppressive immunoregulatory effects of persistent IFN signaling are being increasingly recognized not only during chronic viral infection 99 – 101 but also in cancer 50,51,102,103 .”
Ghaffarpour, S., Ghazanfari, T., Ardestani, S. K., Naghizadeh, M. M., Mahdavi, M. R. V., Salehi, M., Majd, A. M. M., Rashidi, A., Chenary, M. R., Mostafazadeh, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98505-y · Cited by 51
“For example, persevering IFN production can stimulate the expression of PD-L1 ligands, which can inhibit NK cell antiviral action 18 .”
New insights into type I interferon and the immunopathogenesis of persistent viral infections
Snell, L. M., & Brooks, D. G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.03.002 · Cited by 51
PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection
Maine, C. J., Teijaro, J. R., Marquardt, K., & Sherman, L. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603738113 · Cited by 50
“IFN-I is strongly induced immediately after LCMV cl13 infection and is induced in much larger amounts by LCMV cl13 than by the rapidly cleared Armstrong strain of LCMV (21).”
BackgroundResultInfluentialSelf-citationOliviero, B., Mantovani, S., Varchetta, S., Mele, D., Grossi, G., Ludovisi, S., Nuti, E., Rossello, A., & Mondelli, M. U. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.032 · Cited by 46
Menicucci, A. R., Versteeg, K. M., Woolsey, C. B., Mire, C. E., Geisbert, J. B., Cross, R. W., Agans, K. N., Jankeel, A., Geisbert, T. W., & Messaoudi, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01372 · Cited by 50
“A recent study showed production of immunosuppressive mediators IL-10 and PD-L1 is dependent on Type I IFN signaling in a mouse model of lymphocytic choriomeningitis virus infection (68, 69).”
BackgroundThe role of type I interferons in CD4+ T cell differentiation
Kuka, M., Giovanni, M. D., & Iannacone, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.01.013 · Cited by 46
“One interpretation might be that the role of type I IFNs changes based on whether the infection is acute or chronic [10], with interferons supporting CD4+ T cell expansion in the acute phase, but inducing their exhaustion during the chronic phase [29,32,42].”
BackgroundBaral, S., Antia, R., & Dixit, N. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902178116 · Cited by 47
“In other studies, regulatory T cells (8), factors contributing to CD8 T-cell dysfunction (9, 10), type I interferon (IFN) signaling (11, 12), and most recently, host genetics (13) have been argued to influence the outcomes of LCMV infection.”
BackgroundHuber, M., Suprunenko, T., Ashhurst, T. M., Marbach, F., Raifer, H., Wolff, S., Strecker, T., Viengkhou, B., Jung, S. R., Obermann, H.-L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01219-17 · Cited by 47
Minkah, N. K., Wilder, B. K., Sheikh, A. A., Martinson, T., Wegmair, L., Vaughan, A. M., & Kappe, S. H. I. (2019) · Nature Communications · doi:10.1038/s41467-019-11819-0 · Cited by 53
Type I IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection
Labarta-Bajo, L., Nilsen, S. P., Humphrey, G., Schwartz, T., Sanders, K., Swafford, A. D.-E., Knight, R. D., Turner, J. R., & Zúñiga, E. I. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192276 · Cited by 47
Signaling by Type I Interferons in Immune Cells: Disease Consequences
Ζαννίκου, Μ., Fish, E. N., & Platanias, L. C. (2024) · Cancers · doi:10.3390/cancers16081600 · Cited by 45
“However, by blocking IFN-I signaling with a neutralizing antibody against its receptor, this reduced immune system activation, decreased expression of immune checkpoint molecules, resulting in faster viral elimination [154,155].”
BackgroundDallari, S., Macal, M., Loureiro, M. E., Jo, Y., Swanson, L., Hesser, C. R., Ghosh, P., & Zúñiga, E. I. (2017) · Nature Communications · doi:10.1038/ncomms14830 · Cited by 45
Versteeg, K. M., Menicucci, A. R., Woolsey, C. B., Mire, C. E., Geisbert, J. B., Cross, R. W., Agans, K. N., Jeske, D. R., Messaoudi, I., & Geisbert, T. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-09963-y · Cited by 44
Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus
Kahan, S. M., & Zajac, A. J. (2019) · Viruses · doi:10.3390/v11020156 · Cited by 48
“FRCs provide an immune scaffold and facilitate the delivery of chemokines such as CCL19 and CCL21 which recruit T cells and dendritic cells to the T cell zones within lymphoid organs, thus enhancing their interactions.”
BackgroundInfluentialInterim Guidelines on Antiviral Therapy for COVID-19
Kim, S. B., Huh, K., Heo, J. Y., Joo, E., Kim, Y. J., Choi, W. S., Kim, Y., Seo, Y. B., Yoon, Y. K., Ku, N. S., et al. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.2.281 · Cited by 45
“However, previous studies revealed a paradoxical inhibitory effect by suppressing natural killer (NK) cell antiviral function [64] and IFN-γ release from NK cells [65] due to the shift in balance between STAT1 and IFNAR [63].”
BackgroundReis, A. L., Goatley, L. C., Jabbar, T., López, E., Rathakrishnan, A., & Dixon, L. K. (2020) · Vaccines · doi:10.3390/vaccines8020262 · Cited by 44
Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
Broomfield, B. J., Tan, C. W., Qin, R. Z., Abberger, H., Duckworth, B. C., Alvarado, C., Dalit, L., Lee, C. L., Mugan, R. S., Mazrad, Z. A. I., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241148 · Cited by 48
Cancer Immunity: Lessons From Infectious Diseases
Trinchieri, G. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv070 · Cited by 46
“tumor microenvironment largely overlap those observed during resolution of inflammation and exhaustion of the immune response after clearance of infections or during chronic infections [15, 17, 33–35].”
BackgroundImmunopathogenesis of abdominal sepsis
Weber, G. F., & Świrski, F. K. (2013) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-013-1129-7 · Cited by 47
“Applying a neutralizing antibody against the type I interferon (IFN-I) receptor lowers the immune system’s activation state, decreases the expression of negative immune regulatory molecules, measured for example by suppressing interleukin-10 and programmed deathligand 1 (PD-L1), and restores lymphoid architecture duri…”
BackgroundIFN-ε protects primary macrophages against HIV infection
Tasker, C., Subbian, S., Gao, P., Couret, J., Levine, C., Ghanny, S., Soteropoulos, P., Zhao, X., Landau, N. R., Lu, W., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88255 · Cited by 49
Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies
Huot, N., Bosinger, S. E., Paiardini, M., Reeves, R. K., & Müller-Trutwin, M. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00780 · Cited by 43
Snell, L. M., Xu, W., Abd-Rabbo, D., Boukhaled, G. M., Guo, M., MacLeod, B., Elsaesser, H. J., Hezaveh, K., Alsahafi, N., Lukhele, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01060-7 · Cited by 46
Potential Therapeutic Value of the STING Inhibitors
Zhang, S., Zheng, R., Pan, Y., & Sun, H. (2023) · Molecules · doi:10.3390/molecules28073127 · Cited by 45
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer
Bauer, C. A., Kühnemuth, B., Duewell, P., Ormanns, S., Gress, T. M., & Schnurr, M. M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.057 · Cited by 45
Lymphotoxin in physiology of lymphoid tissues – Implication for antiviral defense
Koroleva, E. P., Fu, Y., & Tumanov, A. V. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.018 · Cited by 42
Metadata
- Authors
- Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A.
- Affiliations
- Scripps Research Institute (US)
- Washington University in St. Louis (US)
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
- Corresponding author
- Teijaro, John R.
- Ng, Cherie
- Oldstone, Michael B. A.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3640797
- OpenAlex
- W2024556668
- Cited by
- 755
- References
- 38
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 39 · 2023: 40 · 2022: 42 · 2021: 49 · 2020: 56 · 2019: 55 · 2018: 55 · 2017: 73 · 2016: 86 · 2015: 80 · 2014: 71 · 2013: 37
- FWCI
- 50.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ns041219-10, 5t32ai007354-30)
- National Heart, Lung, and Blood Institute (HL007195, T32HL007195)
- National Cancer Institute (R01CA043059, CA-43059, R37CA043059)
- National Institute of Allergy and Infectious Diseases (AI-077719, AI09484, AI-047140, R01AI009484, AI007354, R01AI047140, T32-AI007354., R56AI077719, R01AI077719, U54AI057160)
- National Institute of Neurological Disorders and Stroke (T32-NS041219, NS-041219)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- lymphocytic choriomeningitis virus, viral persistence, type I interferon signaling, immune activation, negative immune regulation, CD4+ T cells, viral clearance, antiviral therapy
- MeSH terms
- Animals, Antibodies, Viral, Arenaviridae Infections, Dendritic Cells, Female, Immune Tolerance, Interferon Type I, Lymphocytes, Lymphocytic choriomeningitis virus, Male, Mice, Inbred C57BL, Spleen, Viremia, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.